Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation

This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2023-05, Vol.329 (18), p.1607-1608
Main Authors: Tu, S. Sean, Nagar, Sarosh, Kesselheim, Aaron S, Lu, Zhigang, Rome, Benjamin N
Format: Article
Language:English
Subjects:
Commerce - economics
Commerce - legislation & jurisprudence
Commerce - statistics & numerical data
Commerce - trends
Drug delivery
Drugs
Incentives
Legislation, Drug - economics
Legislation, Drug - statistics & numerical data
Letter
Letters
Marketing - economics
Marketing - legislation & jurisprudence
Marketing - statistics & numerical data
Orphan Drug Production - economics
Orphan Drug Production - legislation & jurisprudence
Orphan Drug Production - statistics & numerical data
Pharmaceutical industry
Pharmaceuticals
Prescription drugs
Prescription Drugs - economics
Research Letter
Sales
Tax credits
Taxation
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2023.3079